Skip to main content

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

Active, not recruiting · Phase 1, Phase 2 · NCT05609370

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

At a glance

Research payments reported, 2025
$1.4M
U.S. investigators named
26
Sites paid
27
Planned or actual enrollment
113

About the trial

Sponsor
BeiGene
Tested
Alcestobart (drug), Tislelizumab (drug), Bevacizumab or Bevacizumab biosimilar (drug), Fluoropyrimidine (FP) (drug)
Dates
Started 2023-01-29; completion 2026-12-31
Results posted
Yes

This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

From ClinicalTrials.gov, last updated 2026-07-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Beone Medicines USA, Inc. reported $1.4M in research payments for this study in 2025 (165 payments).

Products named: Tevimbra

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.